Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

MALAT1 Expression is Associated with Aggressive Behavior in Indolent B-Cell Neoplasms

Elena María Fernández-Garnacho, View ORCID ProfileFerran Nadeu, Silvia Martín, View ORCID ProfilePablo Mozas, Andrea Rivero, Julio Delgado, Eva Giné, Armando López-Guillermo, Martí Duran-Ferrer, View ORCID ProfileItziar Salaverria, Cristina López, Sílvia Beà, Santiago Demajo, Pedro Jares, View ORCID ProfileXose S Puente, José Ignacio Martín-Subero, View ORCID ProfileElias Campo, View ORCID ProfileLluís Hernández
doi: https://doi.org/10.1101/2023.02.15.23285907
Elena María Fernández-Garnacho
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferran Nadeu
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ferran Nadeu
Silvia Martín
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo Mozas
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pablo Mozas
Andrea Rivero
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julio Delgado
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Giné
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armando López-Guillermo
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martí Duran-Ferrer
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Itziar Salaverria
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Itziar Salaverria
Cristina López
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sílvia Beà
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santiago Demajo
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Jares
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xose S Puente
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
4University of Oviedo, Oviedo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xose S Puente
José Ignacio Martín-Subero
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
5Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elias Campo
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
3Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain
5Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elias Campo
Lluís Hernández
1Lymphoid Neoplasm Program, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
2Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lluís Hernández
  • For correspondence: hernan{at}recerca.clinic.cat
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

MALAT1 is a long non-coding RNA with oncogenic roles in cancer but poorly studied in indolent B-cell neoplasms. Here, MALAT1 expression was analyzed using RNA-seq, microarrays or qRT-PCR in primary samples from various clinico-biological subtypes of chronic lymphocytic leukemia (CLL, n=266) and follicular lymphoma (FL, n=61). In peripheral blood (PB) CLL samples, high MALAT1 expression was associated with a significantly shorter time to treatment, independently from other known prognostic factors, such as IGHV mutational status. Coding genes whose expression levels were associated with MALAT1 in CLL were predominantly related to oncogenic pathways stimulated in the lymph node (LN) microenvironment. Further analysis of MALAT1 expression by microarrays in paired CLL samples from PB/LN showed that its levels were maintained between both anatomical compartments, supporting that the clinical value of MALAT1 expression found in PB is mirroring expression differences already present in LN. Similarly, high MALAT1 expression in FL predicted for a shorter progression-free survival, and its correlated expressed genes were associated with pathways promoting FL pathogenesis. In summary, MALAT1 expression is related to pathophysiology and clinical behavior of indolent B-cell neoplasms. Particularly in CLL its levels could be a surrogate marker of the microenvironment stimulation and may contribute to refine the clinical management of these patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was funded by Ministerio de Ciencia e Innovacion (MCI), grant numbers RTI2018-094274-B-I00 to EC.; Fundacio La Marato de TV3 (projecte financat per Fundacio La Marato de TV3) 201920-30 to LH. Suport Grups de Recerca AGAUR 2014-SGR-795 and 2017-SGR-736 of the Generalitat de Catalunya to EC and JIM-S., respectively. AGAUR 2018 FIB00696, Generalitat de Catalunya to EMF-G. EC and JIM-S are Academia Researchers of the "Institucio Catalana de Recerca i Estudis Avancats" (ICREA) of the Generalitat de Catalunya.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Hospital Clinic de Barcelona gave ethical approval for this work as FL samples were obtained from the Hematopathology collection of the Biobank of Hospital Clinic de Barcelona-IDIBAPS and CLL samples data and clinical annotations were obtained from the project of the Spanish ICGC consortium. The remaining data from other samples were obtained from GEO microarray public repository including previously published works with their particular ethical compliances stated in the original articles.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 23, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
MALAT1 Expression is Associated with Aggressive Behavior in Indolent B-Cell Neoplasms
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
MALAT1 Expression is Associated with Aggressive Behavior in Indolent B-Cell Neoplasms
Elena María Fernández-Garnacho, Ferran Nadeu, Silvia Martín, Pablo Mozas, Andrea Rivero, Julio Delgado, Eva Giné, Armando López-Guillermo, Martí Duran-Ferrer, Itziar Salaverria, Cristina López, Sílvia Beà, Santiago Demajo, Pedro Jares, Xose S Puente, José Ignacio Martín-Subero, Elias Campo, Lluís Hernández
medRxiv 2023.02.15.23285907; doi: https://doi.org/10.1101/2023.02.15.23285907
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
MALAT1 Expression is Associated with Aggressive Behavior in Indolent B-Cell Neoplasms
Elena María Fernández-Garnacho, Ferran Nadeu, Silvia Martín, Pablo Mozas, Andrea Rivero, Julio Delgado, Eva Giné, Armando López-Guillermo, Martí Duran-Ferrer, Itziar Salaverria, Cristina López, Sílvia Beà, Santiago Demajo, Pedro Jares, Xose S Puente, José Ignacio Martín-Subero, Elias Campo, Lluís Hernández
medRxiv 2023.02.15.23285907; doi: https://doi.org/10.1101/2023.02.15.23285907

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)